DUPIXENT SIGNIFICANTLY REDUCED
COPD EXACERBATIONS1-3,a

 

Annualized rate of moderate or severe COPD exacerbations at Week 52
(primary endpoint)

Number needed
to treat (NNT):

Based on pooled analysis of BOREAS and NOTUS

For every

3

patients
on DUPIXENT,

1

moderate or severe
exacerbation was prevented4

The annualized rate of moderate or severe exacerbations for the DUPIXENT and placebo
arms in the pooled analysis was 0.794 and 1.156, respectively (rate ratio 0.687, 95% CI 0.595, 0.793).

Definitive conclusions cannot be reached as the pre-specified pooled analysis was not controlled for multiplicity and the low exacerbation rate observed in the control group might limit the generalizability of our findings.

EXACERBATION REDUCTION DATA
across baseline EOS levels4

Based on a post hoc analysis of the pooled BOREAS and NOTUS data
of patients with EOS ≥300 cells/μL at screening
  • All patients in BOREAS and NOTUS had at least 1 eosinophil count of ≥300 cells/μL during the
    4-week screening period
    • 40% of patients had blood EOS <300 cells/μL at baseline

Annualized rate of moderate or severe COPD exacerbations at Week 52
(post hoc analysis) stratified by baseline blood eosinophil count5,a,*

Definitive conclusions cannot be reached as the pre-specified pooled analysis was not controlled for multiplicity and the low exacerbation rate observed in the control group might limit the generalizability of our findings.

*All patients had at least one eosinophil count ≥300 cells/μL during the 4-week screening, per study criteria.

Placebo + triple therapy DUPIXENT + triple therapy

aModerate exacerbations were defined as exacerbations that resulted in treatment with a systemic glucocorticoid, an antibiotic agent, or both. Severe exacerbations were defined as exacerbations that led to hospitalization or an emergency medical care visit or that resulted in death.1-3

COPD, chronic obstructive pulmonary disease.